Patents by Inventor Ole Juul Nordfang

Ole Juul Nordfang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110059894
    Abstract: The invention provides a method for preventing formation of inhibitors to blood coagulation factor VIII or factor IX in a subject having haemophilia, the method comprising administering (via intravenous, subcutaneous, intradermal, or intramuscular routes) to a previously untreated subject an effective dosage of factor VIIa or a factor VII-related polypeptide.
    Type: Application
    Filed: November 12, 2010
    Publication date: March 10, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Lisa Payne Rojkjaer, Marie Johannessen, Ole Juul Nordfang, Jens Aas Jansen
  • Patent number: 7786070
    Abstract: The invention relates to the use of a Factor VIIa for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, said medicament being for subcutaneous, intramuscular or intradermal administration, and to the use of a Factor VIIa for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, wherein said medicament, when administered subcutaneously, intradermally or intramuscularly, shows a prolonged biological half-life.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: August 31, 2010
    Assignee: Novo Nordisk HealthCare A/G
    Inventors: Marie Johannessen, Ole Juul Nordfang, Jens Aas Jansen
  • Publication number: 20080145914
    Abstract: The invention relates to the use of a Factor VIIa for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, said medicament being for subcutaneous, intramuscular or intradermal administration, and to the use of a Factor VIIa for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, wherein said medicament, when administered subcutaneously, intradermally or intramuscularly, shows a prolonged biological half-life.
    Type: Application
    Filed: October 30, 2002
    Publication date: June 19, 2008
    Inventors: Marie Johannessen, Ole Juul Nordfang, Jens Aas Jansen
  • Patent number: 6833352
    Abstract: The invention relates to a pharmaceutical composition comprising Factor VIIa for subcutan, intramuscular or interdermal administration. Factor VIIa administered subcutanously, intramuscularly or intradermally shows a sufficient transport into the bloodstream in biologically active form and in adequate concentrations, and favorable pharmacokinetic properties.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: December 21, 2004
    Assignee: Novo Nordisk Pharmaceuticals, Inc.
    Inventors: Marie Johannessen, Ole Juul Nordfang, Jens Aas Jansen
  • Publication number: 20020115590
    Abstract: The invention relates to a pharmaceutical composition comprising Factor VIIa for subcutan, intramuscular or interdermal administration.
    Type: Application
    Filed: October 25, 2001
    Publication date: August 22, 2002
    Inventors: Marie Johannessen, Ole Juul Nordfang, Jens Aas Jansen
  • Patent number: 6310183
    Abstract: The invention relates to a pharmaceutical composition comprising Factor VIIa for subcutan, intramuscular or interdermal administration. Factor VIIa administered subcutanously, intramuscularly or intradermally shows a sufficient transport into the bloodstream in biologically active form and in adequate concentrations, and favorable pharmacokinetic properties.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: October 30, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Marie Johannessen, Ole Juul Nordfang, Jens Aas Jansen